Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$28.7 million.

  • X4 Pharmaceuticals' Cash from Investing Activities fell 7997.99% to -$28.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.3 million, marking a year-over-year decrease of 12446.52%. This contributed to the annual value of $67.0 million for FY2024, which is 55011.09% up from last year.
  • Latest data reveals that X4 Pharmaceuticals reported Cash from Investing Activities of -$28.7 million as of Q3 2025, which was down 7997.99% from $23.1 million recorded in Q2 2025.
  • Over the past 5 years, X4 Pharmaceuticals' Cash from Investing Activities peaked at $96.9 million during Q2 2024, and registered a low of -$28.7 million during Q3 2025.
  • For the 5-year period, X4 Pharmaceuticals' Cash from Investing Activities averaged around $2.2 million, with its median value being -$86000.0 (2021).
  • Examining YoY changes over the last 5 years, X4 Pharmaceuticals' Cash from Investing Activities showed a top increase of 208325.14% in 2024 and a maximum decrease of 5903333.33% in 2024.
  • Quarter analysis of 5 years shows X4 Pharmaceuticals' Cash from Investing Activities stood at -$13000.0 in 2021, then tumbled by 161.54% to -$34000.0 in 2022, then tumbled by 14114.71% to -$4.8 million in 2023, then tumbled by 78.38% to -$8.6 million in 2024, then tumbled by 232.55% to -$28.7 million in 2025.
  • Its Cash from Investing Activities stands at -$28.7 million for Q3 2025, versus $23.1 million for Q2 2025 and -$3.1 million for Q1 2025.